Skip to contentH
Halozyme Therapeutics, Inc.
H
HALOHalozyme Therapeutics, Inc. Q2 2020 · 10-Q
Revenue$55.22M$55.22M+41.1% vs Q2 2019 Net Income$25.82M$25.82MN/M vs Q2 2019 EPS Diluted$0.19$0.19N/M vs Q2 2019 Gross Profit$597,000−84.6% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Halozyme Therapeutics, Inc. · CIK 1159036 · Engraved from SEC EDGAR
Operating Cash Flowderived$3,294,000N/M Free Cash Flowderived$2,779,000N/M Margins · derivedGross margin1.1%−8.8 pt vs Q2 2019
Operating margin53.5%+89.2 pt vs Q2 2019
Net margin46.8%+84.1 pt vs Q2 2019
ended Jun 30, 2020 · filed Aug 10, 2020 · 41 d after period end